Intensity-Modulated Radiation Therapy (IMRT) of the Prostate
Intensity-modulated radiation therapy is considered investigational when used in combination with radioactive implant treatment (brachytherapy).
Intensity-modulated radiation therapy (IMRT) of the prostate is considered investigational for other indications not listed as medically necessary.
Intra-fraction image guidance systems* (i.e., real-time within fraction image guidance) used with IMRT are considered not medically necessary. (See Related Policies).
*Examples of the imaging devices include: Calypso® 4D Localization System, AlignRT® radiotherapy positioning system, RayPilot® 4D intra-fraction image guidance system.
77301 Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specification.
77418 Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
0073T Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session.
77338 Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
Code 77338 is to be reported only once per IMRT plan and should not be reported with 0073T.
Radiation therapy is an integral component in the treatment of prostate cancer. Intensity-modulated radiation therapy (IMRT) has been proposed as a method of radiation therapy that allows adequate radiation therapy to the tumor while minimizing the radiation dose to surrounding normal tissues and structures.
For prostate cancer, external-beam radiation therapy (EBRT) is one accepted option for treatment.
Conventional external-beam radiation therapy (EBRT)
Over the past several decades, methods to plan and deliver radiation therapy have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional treatment planning based on flat images, and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed “conventional external beam radiation therapy” (EBRT).
3-Dimensional conformal radiation therapy (3D-CRT)
Treatment planning evolved by using 3-dimensional images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction, and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed 3-dimensional conformal radiation therapy (3D-CRT).
Intensity-modulated radiation therapy (IMRT)
IMRT uses computer software and CT and magnetic resonance imaging (MRI) images that offer better conformality than 3D-CRT, as it is able to modulate the intensity of the overlapping radiation beams projected on the target and to use multiple shaped treatment fields. It uses a device (a multi-leaf collimator, [MLC]) which, coupled to a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor and surrounding tissues and organs at risk, computer software optimizes the location, shape and intensities of the beam ports, to achieve the treatment plan’s goals.
Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity (e.g., proctitis), and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.
Since most tumors move as patients breathe, dosimetry with stationary targets may not accurately reflect doses delivered within target volumes and adjacent tissues in patients. Furthermore, treatment planning and delivery are more complex, time-consuming, and labor-intensive for IMRT than for 3D-CRT. Thus, clinical studies must test whether IMRT improves tumor control or reduces acute and late toxicities, when compared with 3D-CRT.
Methodologic Issues in IMRT research
Multiple-dose planning studies have generated 3D-CRT and IMRT treatment plans from the same scans, then compared predicted dose distributions within the target and in adjacent organs at risk. Results of such planning studies show that IMRT improves on 3D-CRT with respect to conformality to, and dose homogeneity within, the target. Dosimetry using stationary targets generally confirms these predictions. Thus, radiation oncologists hypothesized that IMRT may improve treatment outcomes compared with those of 3D-CRT. However, these types of studies offer indirect evidence on treatment benefit from IMRT, and it is difficult to relate results of dosing studies to actual effects on health outcomes.
Comparative studies of radiation-induced side effects from IMRT versus alternative radiation delivery are probably the most important type of evidence in establishing the benefit of IMRT. Such studies would answer the question of whether the theoretical benefit of IMRT in sparing normal tissue translates into real health outcomes. Single-arm series of IMRT can give some insights into the potential for benefit, particularly if an adverse effect that is expected to occur at high rates is shown to decrease by a large amount. Studies of treatment benefit are also important to establish that IMRT is at least as good as other types of delivery, but in the absence of such comparative trials, it is likely that benefit from IMRT is at least as good as with other types of delivery.
Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply.
This plan specific policy was originally created in 2012 and is updated with searches of the MEDLINE database. The most recent literature search was performed for the period of January 2012 through April 2013. The following is a summary of the key findings to date.
Intensity-modulated radiation therapy (IMRT) detects the areas of radiation and adjusts the dose weighting and delivery to process the radiation plan. In contrast to 3-dimensional conformal radiotherapy (3D-CRT) that is accurate to within 7 to 10 mm, IMRT restricts the dose and provides accuracy within 1 to 3 mm. The policy focuses on systematic reviews that evaluate outcomes of IMRT treatments in patients with prostate cancer. Also included are summaries of data from the systematic reviews and representative primary studies on adverse effects of treatment. A reduction in adverse effects is likely to be the greatest potential benefit of IMRT.
In 2012, Bauman and colleagues published a systematic review that examined the evidence for IMRT in the treatment of prostate cancer in order to quantify its potential benefits and to make recommendations for radiation treatment programs considering adopting this technique within the province of Ontario, Canada. (1) Based on a review of 11 published reports through March 2009 (nine retrospective cohort studies and two randomized clinical trials [RCTs]) including 4,559 patients, the authors put forth the recommendation for IMRT over 3D-CRT for aggressive treatment of localized prostate cancer where an escalated radiation (>70 Gy) dose is required. There were insufficient data to recommend IMRT over 3D-CRT in the postoperative setting. (1)
Nine of 11 studies reviewed by Bauman and colleagues reported on adverse effects. Six of 9 studies reported on acute gastrointestinal (GI) effects. (1) Four studies (3 retrospective cohort studies and 1 RCT) reported differences in adverse effects between IMRT and 3D-CRT. The RCT included a total of 78 patients, and reported that acute GI toxicity was significantly less frequent in the IMRT group compared to 3D-CRT. This was true for grade 2 or higher toxicities (20% vs. 61%, p=0.001), grade 3 or higher toxicity (0 vs. 13%, p=0.001) and for acute proctitis (15% vs. 38%, p=0.03). In contrast, the second RCT included in this systematic review reported that there were no differences in toxicity between IMRT and 3D-CRT. (1)
Six of 9 studies reported on acute genitourinary (GU) effects. One study, which was a retrospective cohort study including 1,571 patients, reported a difference in overall acute GU effects in favor of 3D-CRT (37% IMRT vs. 22% 3D-CRT, p=0.001). For late GI toxicity, 4 of 9 studies, all retrospective cohort studies with a total of 3,333 patients, reported differences between IMRT and 3D-CRT. One RCT reported on late GI toxicity and did not find any differences between IMRT and 3D-CRT. Five of 9 studies reported on late GU effects, and only one reported a difference in late GU effects in favor of 3D-CRT (20% vs. 12%, p=0.01). Two retrospective cohort studies reported mixed findings on quality of life outcomes. (1) A subsequent economic analysis (based on this systematic review data) demonstrated that for radical radiation treatment (>70 Gy) of prostate cancer, IMRT seems to be cost-effective when compared with an equivalent dose of 3D-CRT from the perspective of the Canadian health care system for 2009. (2)
In 2008, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review comparing the relative effectiveness and safety of various treatments for clinically localized prostate cancer. (3) Studies on IMRT were included in the assessment under the category of EBRT. Based on review of randomized control trials (RCTs) and nonrandomized studies published from 2000 to September 2007, there was no direct evidence (i.e. from RCTs) that IMRT results in better survival or disease-free survival (DFS) than other therapies for localized prostate cancer. Based on case-series data, the absolute risks of clinical and biochemical outcomes (including tumor recurrence), toxicity, and quality of life after IMRT were comparable with conformal radiation. For IMRT, the percent of patients with Grade 1 and 2 acute gastrointestinal (GI) toxicity was 22% and 4%, respectively, the percent of patients with rectal bleeding was 1.6–10% and the percent of patients with Grade 2 genitourinary (GU) toxicity was 28%-31%. This review concluded that there was low-level evidence that IMRT provides at least as good a radiation dose to the prostate with less radiation to the surrounding tissues (that is undesirable) compared with conformal radiation therapy.(3)
In 2010, an update of the 2008 AHRQ systematic review was undertaken by the AHRQ Technology Assessment Program. (4) As with the 2008 review, this review concluded that the available data were insufficient to compare the effectiveness of the various forms of radiation treatments. Studies on IMRT were included in the assessment under the category of external-beam radiation therapy (EBRT) and thus reported data were not specific to IMRT. While higher EBRT dosages may result in longer-term biochemical control than lower EBRT dosages, overall and disease-specific survival data were inconclusive. Additionally, GU and GI toxicities experienced with EBRT did not seem to differ when standard fractionation was compared to moderate hypofractionization. The authors noted the need for further studies to evaluate outcomes of IMRT for the treatment of prostate cancer. (4) In addition, a subsequent report undertaken by the AHRQ Comparative Effectiveness Review Surveillance Program using the search strategy employed for the 2008 systematic review found no new data on IMRT following a limited literature search of the MEDLINE database through March 2012. (5)
Similar findings were observed in a systematic review of the clinical effectiveness of IMRT for the radical treatment of prostate cancer undertaken by the U.K. Health Technology Assessment Programme in 2010. (6) The authors also performed an economic analysis which demonstrated IMRT to be cost-effective from the perspective of the U.K. National Health Service for 2008/09 if this treatment modality can be used to prolong survival. (7)
An earlier review by the Institute for Clinical and Economic Review (8) reached the following conclusions in 2007:
“The literature on comparative rates of toxicity has serious methodological weaknesses. There are no prospective randomized trials or cohort trials, and the case series that exist are hampered by the lack of contemporaneous cohorts and/or by a failure to describe the selection process by which patients were assigned to IMRT vs. 3D-CRT. Published case series demonstrate consistent findings of a reduced rate of GI toxicity for IMRT at radiation doses from approximately 75–80 Gy [grays]. Data on genitourinary (GU) toxicity have not shown superiority of IMRT over 3D-CRT, nor does the existing data suggest that IMRT provided a lower risk of erectile dysfunction.”
“The literature suggests that the risk of Grade 2 GI toxicity is approximately 14% with 3D-CRT and 4% with IMRT. Thus, the number of patients needed to treat to prevent one case of moderate-severe proctitis is 10, and for every 100 patients treated with IMRT instead of 3D-CRT, 10 cases of GI toxicity would be expected to be prevented.”
Primary studies reporting on outcomes and adverse effects
While the use of IMRT for prostate cancer has increased significantly, only a few institutions have reported long-term data on biochemical control rates and toxicity. Vora and colleagues reported on 9-year tumor control and chronic toxicities observed in 302 patients treated with IMRT for clinically localized prostate cancer at one institution. (9) The median dose delivered was 76 Gy (range 70-77 Gy), and 35% of patients received androgen deprivation therapy. Local and distant recurrence rates were 5% and 8.6%, respectively. At 9 years, biochemical control rates were close to 77% for low-risk, 70% for intermediate-risk, and 53% for high-risk patients (log rank p=0.05). At last follow-up, only 0%/0.7% had persistent grade ≥3 GI/GU toxicity. The high-risk group was associated with a higher distant metastasis rate (p=0.02) and death from prostate cancer (p=0.001). (9)
Alicikus and colleagues reported on 10-year outcomes in 170 patients treated after high-dose IMRT (81 Gy). (10) The 10-year actuarial prostate-specific antigen (PSA) relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group. The 10-year distant metastases–free rates were 100%, 94%, and 90%, respectively, and cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary toxicity was 11% and 5%, respectively, and the likelihood of developing grade 2 and 3 late gastrointestinal toxicity was 2% and 1%, respectively. No grade 4 toxicities were observed. These findings indicate that IMRT is associated with good long-term tumor-control and low rates of serious toxicity in patients with localized prostate cancer. (10)
In 2008 Zelefsky and colleagues reported on the incidence and predictors of treatment-related toxicity at 10 years after 3D-CRT and IMRT for localized prostate cancer. (11) Between 1988 and 2000, 1,571 patients with stages T1-T3 prostate cancer were treated with 3D-CRT or IMRT with doses ranging from 66 to 81 Gy. Twenty-two percent were considered to be at low risk, as based on National Comprehensive Cancer Network (NCCN) guidelines. The median follow-up was 10 years. The actuarial likelihood at 10 years for the development of Grade 2 or higher GI toxicities was 9%. The use of IMRT significantly reduced the risk of GI toxicities compared with patients treated with conventional 3D-CRT (13% to 5%; p<0.001). Among patients who experienced acute symptoms, the 10-year incidence of late toxicity was 42%, compared with 9% for those who did not experience acute symptoms. The 10-year incidence of late Grade 2 or higher GU toxicity was 15%. Patients treated with 81 Gy (IMRT) had a 20% incidence of GU symptoms at 10 years, compared with 12% for patients treated with lower doses (p=0.01). Among patients who had developed acute symptoms during treatment, the incidence of late toxicity at 10 years was 35%, compared with 12%. The incidence of Grade 3 GI and GU toxicities was 1% and 3%, respectively. The authors concluded that serious late toxicity was unusual despite the delivery of high radiation dose levels in these patients. They also noted that higher doses were associated with increased GI and GU Grade 2 toxicities, but the risk of proctitis was significantly reduced with IMRT.
Cahlon and colleagues reported on preliminary biochemical outcomes and toxicity with high-dose IMRT to a dose of 86.4 Gy for localized prostate cancer. (12) For this study, 478 patients were treated between August 1997 and March 2004 with 86.4 Gy using a 5- to 7-field IMRT technique. The median follow-up was 53 months. Thirty-seven patients (8%) experienced acute Grade 2 GI toxicity; none had acute Grade 3 or 4 GI toxicity; 105 patients (22%) experienced acute Grade 2 GU toxicity; and 3 patients (0.6%) had Grade 3 GU toxicity. Sixteen patients (3%) developed late Grade 2 GI toxicity; 2 patients (<1%) developed late Grade 3 GI toxicity; 60 patients (13%) had late Grade 2 GU toxicity; and 12 (<3%) experienced late Grade 3 GU toxicity. The 5-year actuarial PSA relapse-free survival, according to the nadir plus 2 ng/mL definition, was 98%, 85%, and 70% for the low-, intermediate-, and high-risk NCCN prognostic groups. The authors concluded that treatment with ultra-high radiation dose levels of 86.4 Gy using IMRT for localized prostate cancer is well tolerated and the early excellent biochemical control rates are encouraging. These results based on a case series should be considered as preliminary.
In 2009, Wong and colleagues reported on a retrospective study of radiation dose escalation in 853 patients with localized (T1c-T3N0M0) prostate cancer. (13) Radiation therapies used included conventional dose (71 Gy) 3D-CRT (n=270), high-dose (75.6 Gy) IMRT (n=314), permanent transperineal brachytherapy (n=225) and external beam radiotherapy (EBRT) plus brachytherapy boost (n=44). All patients were followed for a median of 58 months (range, 3 to 121 months). The authors reported:
“The 5-year overall survival for the entire group was 97%. The 5-year [biochemical control] bNED rates, local control rates, and distant control rates were 74%, 93%, and 96%, respectively, for 3D-CRT; 87%, 99%, and 97%, respectively, for IMRT; 94%, 100%, and 99%, respectively, for BRT alone; and 94%, 100%, and 97%, respectively, for EBRT + BRT. The bNED rates for 3D-CRT were significantly less than those of the other higher dose modalities (P<.0001).”
Intermediate- and high-risk prostate cancer patients in this study had significantly improved 5-year bNED rates with dose escalation. However, in low-risk prostate cancer patients, bNED rates with dose escalation were not improved compared to conventional dose 3D-CRT. The authors also found acute and late grade 2 and 3 GU toxicities were fewer with IMRT than brachytherapy or EBRT plus brachytherapy.
Studies of post-prostatectomy IMRT have demonstrated superior dose distribution to the target volume with the use of IMRT, as compared with 3D conformal radiation delivery, with better sparing of nearby critical healthy tissue structures and less severe toxicity-related morbidity (14).
In 2009, Thompson, et al. reported on the long-term follow-up of a randomized clinical trial of radiotherapy to reduce the risk of metastatic disease in men who had radical prostatectomy surgery. A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival. Of 425 eligible men 211 were randomized to observation and 214 to adjuvant radiation. In the group of men under observation 70 ultimately received radiotherapy. Metastasis-free survival was reported as significantly greater with radiotherapy (93 of 214 events on the radiotherapy arm vs. 114 of 211 events on observation; HR 0.71; 95% CI 0.54, 0.94; p = 0.016). Survival improved with adjuvant radiation (88 deaths of 214 on the radiotherapy arm vs. 110 deaths of 211 on observation; HR 0.72; 95% CI 0.55, 0.96; p = 0.023). The authors concluded that adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival. (15)
External beam Radiation Therapy and Brachytherapy
Brachytherapy in combination with EBRT to boost therapeutic effect is one method used by some radiation oncologists for treating high-risk prostate cancer patients. Some authors have suggested that all patients undergoing brachytherapy should receive combined therapy. Sylvester et al. reported the Seattle experience with the 15-year biochemical relapse-free survival (BRFS) for 223 patients. (16) Several published articles supporting the use of external EBRT and brachytherapy are based on the retrospective data from this study. One Phase III clinical trial started in 2003 is focused on Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone and may offer guidance about this therapy in the future. Until further strong research is completed, a review of the current literature does not allow any firm conclusions thus this combination treatment strategy is considered investigational.
Ongoing Clinical Trials
A search of Clinicaltrials.gov identified several Phase III randomized clinical trials of IMRT for prostate cancer. Some trials were identified comparing IMRT to other radiation modalities for the treatment of prostate cancer.
One Phase III randomized clinical trial is comparing IMRT to proton beam therapy to determine which therapy best minimizes the side effects of treatment (NCT01617161). This trial has an estimated enrollment of 461 patients and is sponsored by the Massachusetts General Hospital in collaboration with the University of Pennsylvania and the National Cancer Institute. The primary outcome measure is disease-free survival at 5 years. This study is currently recruiting participants with the estimated completion date of January 2016.
In a Canadian randomized Phase III trial, 3D-CRT is being compared to helical tomotherapy IMRT in high-risk prostate cancer patients (NCT00326638). This trial has an estimated enrollment of 72 patients and is sponsored by the Ottawa Hospital Research Institute. The primary outcome measure is late rectal toxicity from radiotherapy of the prostate. This study is currently recruiting participants with the estimated completion date of May 2014.
In another randomized Phase III trial, hypofractionated 3D-CRT or IMRT is being compared to conventionally fractionated 3D-CRT or IMRT in favorable-risk prostate cancer (NCT00331773). This trial has an estimated enrollment of 1,067 patients and is sponsored by the Radiation Therapy Oncology Group-National Cancer Institute. The primary outcome measure is disease-free survival at 5 years. This study is currently recruiting participants with the estimated completion date of February 2021.
A randomized ongoing Phase III trial studying the adverse effects of 3 schedules of IMRT in treating patients with localized prostate cancer is being undertaken by the U.K. Institute of Cancer Research (NCT00392535). This is a multicenter trial (n=26 centers) with an estimated enrollment of 2,163 patients. The primary outcome measures are acute and late radiation-induced side effects and freedom from prostate cancer recurrence. This study completion date was September 2012, but final results are not published. Preliminary results of this study published in 2008 report that hypofractionated IMRT (57-60 Gy) seems equally well-tolerated as conventionally fractionated treatment (74 Gy) at 2 years of follow-up. (17)
Another ongoing Phase III trial is Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma (NCT00063882). This trial has an estimated enrollment of 600 patients and is sponsored by the Radiation Therapy Oncology Group-National Cancer Institute. This study has an estimated completion date of January 2017.
In general, when the radiation doses are similar the available evidence suggests that IMRT in the treatment of prostate cancer provides tumor control rates comparable to existing radiotherapy techniques. In addition, while results are not uniform and are based on retrospective cohort trials, some studies show reductions in GI and GU toxicity. A reduction in clinically significant complications of radiation therapy is likely to lead to an improved quality of life for treated patients. Thus, based on the published literature that provides data on outcomes of treatment, IMRT is another technique that can be used to deliver radiation therapy in the treatment of localized prostate cancer, and its use for this clinical application may be considered medically necessary.
Practice Guidelines and Position Statements
The most recent National Comprehensive Cancer Network (NCCN) guidelines (v.2.2013) for prostate cancer indicate, in the principles of radiation therapy, the external-beam radiotherapy techniques of three-dimensional conformal (3D-CRT), or IMRT, should be employed. (18) The NCCN guidelines also indicate 3D-CRT or IMRT may be considered as an initial treatment option in all prostate cancer patients except for patients with a very-low risk of recurrence and less than 20 years’ expected survival.
The American College of Radiology Appropriateness Criteria indicates IMRT is appropriate for field shaping in patients being treated for clinically localized prostate cancer. (19) Additionally, the ACR guidelines indicate IMRT is most appropriate for treatment planning for dose escalation.
The U.S. Preventive Services Task Force (USPSTF) recommendations on screening for prostate cancer include the following statements: “Even if prostate cancer screening is determined to be effective, the length of time required to experience a mortality benefit is greater than 10 years. Because a 75-year-old man has an average life expectancy of about 10 years, very few men age 75 years or older would experience a mortality benefit. Similarly, men younger than age 75 years who have chronic medical problems and a life expectancy of fewer than 10 years are also unlikely to benefit from screening and treatment.” Available at URL address: http://annals.org/article.aspx?articleid=742052. Last accessed May 8, 2013.
Medicare National Coverage
There is no national coverage determination.
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specification
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session
Malignant neoplasm of prostate
Malignant neoplasm of prostate
Excerpt from the TNM staging system for prostate cancer from the American Joint Committee on Cancer (AJCC) retrieved from: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-staging (Last accessed May 8, 2013).
N=regional lymph nodes
T1 – tumor is found incidentally in the prostate and is less than 5% of tissue removed by needle biopsy
T2 – tumor is more advanced than T1 but remains confined to the prostate
T3 – tumor extends beyond the prostatic capsule
T3a – extracapsular invasion unilateral or bilateral
T3b – invasion of the seminal vesicle(s)
T4 – tumor invades tissue next to the prostate (other than the seminal vesicles) such as urethral sphincter, rectum, bladder and/or pelvic wall
N0 – without lymphatic invasion
M0 – without metastasis
New policy – Add to Therapy section. Recommended for adoption by OAP on November 17, 2011. Approved with 90-day hold for provider notification, effective September 1, 2012.
Related Policies updated: 8.01.59 added and 8.01.525 replaced with 8.01.48, all effective as of September 1, 2012.
Add Related Policy: 2.03.10.
Implementation delayed to January 1, 2013.
Replace policy. Policy is updated and is different than what was published on the public medical policy website before this date. Policy revised with input from clinical vetting. Policy statement now says IMRT is medically necessary for treatment of localized cancer in an intact prostate and for treatment after prostatectomy surgery when criteria are met. Intra-fraction imaging is added as not medically necessary. Description and rationale sections revised based on literature review through October 2012. New references added; others renumbered or removed. Policy statement changed as noted. Policy effective date is January 1, 2013, as was previously noted to allow for provider notification.
Replace policy. Policy statement for post-prostatectomy IMRT changed to read: “the prostate specific antigen (PSA) remains detectable after the first 6 months of surgery”. Added related policies: 6.01.10, 8.01.10. Rationale updated based on a literature review through April 2013. References 1, 2, 5-7, 9, 10, 14 added; others renumbered or removed. Policy statement changed as noted.
Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).